Biovista Announces Research Collaboration With a Major Pharmaceutical Company

CHARLOTTESVILLE, Virginia, April 27, 2011 /PRNewswire/ -- Biovista announced today that it has entered into a research collaboration agreement with Novartis. The collaboration is focused on identifying new indications for a number of undisclosed Novartis compounds using Biovista's Clinical Outcome Search Space (COSS) technology.

The terms of the agreement include an upfront payment and success-based milestones.

"We look forward to working with Novartis to enhance their drug discovery efforts" said Aris Persidis, President of Biovista. "Our unique COSS(tm) technology offers significant advantages in terms of speed, comprehensiveness and depth of clinical outcome exploration, which we expect will help patients in need of novel solutions," he added.

About Biovista:

Biovista is a privately held biotechnology company that finds novel uses for existing drugs, and profiles their side effects using their mechanism of action. Biovista is developing its own drug pipeline in multiple indications and is collaborating with the FDA on the prediction of adverse events, as well as with biopharmaceutical companies on indication expansion and de-risking of their portfolios (

    For further information please contact:

    Aris Persidis
    Biovista, Inc.
    [email protected]

SOURCE Biovista

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.